The Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific cellular therapies, signed a long-term supply contract with our network member Matricel GmbH for the ACI-Maix collagen-membrane. In a press release from October 26th 2015, the CEO of Vericel Corporation Nick Colangelo announced: “Matricel’s proprietary collagen scaffold technology and previous experience as a reliable supplier of the ACI-Maix membrane for MACI make Matricel a valuable partner for us as we pursue registration of MACI in the United States. We look forward to a long and productive relationship with Matricel.” (Source: www.marketwired.com)
